Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: Determination of epithelial lining fluid targets

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3325-3330

  Louie, Arnold ^a   Fregeau, Christine ^a   Liu, Weiguo ^a   Kulawy, Robert ^a   Drusano, G L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; FEMALE; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; EPITHELIUM; FEMALE; MICE; OFLOXACIN; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 67749147359     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00006-09     Document Type: Article

References (23)

1. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44: 79-86.
2. American Thoracic Society and Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
3. Andes, D., and W. A. Craig. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46:1665-1670.
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. CLSI publication M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Combes, A., C. E. Luyt, J. Y. Fagon, M. Wolff, J. L. Trouillet, and J. Chastre. 2007. Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia. Crit. Care Med. 35:146-154.
6. Craig, W. A., and D. R. Andes. 2008. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob. Agents Chemother. 52:3492-3496.
7. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. http://bmsr.usc.edu/.
8. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: the interactions between bug and drug. Nat. Rev. Microbiol. 2:289-300.
9. Drusano, G. L., S. L. Preston, M. H. Gottfried, L. H. Danziger, and K. A. Rodvold. 2002. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46:586-589.
10. Plasma ratio in healthy volunteers, abstr. A-1902. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC, 25 to 28 October 2008.
11. Du, X., C. Li, H. K. Sun, C. H. Nightingale, and D. P. Nicolau. 2005. A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC. J. Pharm. Biomed. Anal. 39:648-652.
12. Fink, M. P., D. R. Snydman, M. S. Niederman, K. V. Leeper, Jr., R. H. Johnson, S. O. Heard, R. G. Wunderink, J. W. Caldwell, J. J. Schentag, G. A. Siami, R. L. Zameck, D. C. Haverstock, H. H. Reinhart, R. M. Echols, and the Severe Pneumonia Study Group. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 38:547-557.
13. Garcia-Medina, R., W. M. Dunne, P. K. Singh, and S. L. Brody. 2005. Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells. Infect. Immun. 73:8298-8305.
14. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in-vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
15. Kollef, K. E., G. E. Schramm, A. R. Wills, R. M. Reichley, S. T. Micek, and M. H. Kollef. 2008. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 134:281-287.
16. Laohavaleeson, S., P. R. Tessier, and D. P. Nicolau. 2008. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob. Agents Chemother. 52:2389-2394.
17. Leary, R., R. Jelliffe, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. In Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
18. Lodise, T. P., S. L. Preston, V. Barghava, A. Bryskier, R. Nusrat, S. Chapel, M. Rangaraju, and G. L. Drusano. 2005. Pharmacodynamics of an 800 mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn. Microbiol. Infect. Dis. 52:45-52.
19. Ong, C. T., P. K. Dandekar, C. Sutherland, C. H. Nightingale, and D. P. Nicolau. 2005. Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy 51:339-346.
20. Peloquin, C. A., T. J. Cumbo, D. E. Nix, M. F. Sands, and J. J. Schentag. 1989. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch. Intern. Med. 149:2269-2273.
21. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, R. Leary, and G. L. Drusano. 2005. Bacterial population responses to drug selective pressure: examination of garenoxacin against Pseudomonas aeruginosa. J. Infect. Dis. 192:420-428.
22. Tam, V. H., A. Louie, T. R. Fritsche, M. Deziel, W. Liu, D. L. Brown, L. Deshpande, R. Leary, R. N. Jones, and G. L. Drusano. 2007. Drug exposure intensity and duration of therapy's impact on emergence of resistance of Staphylococcus aureus to a quinolone antimicrobial. J. Infect. Dis. 195:1818-1827.
23. Waine, D. J., D. Honeybourne, E. G. Smith, J. L. Whitehouse, and C. G. Dowson. 2008. Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa. J. Clin. Microbiol. 46:3491-3493.